FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2667-2676 June 22, 2006 Number 25 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Tan, F. K. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Systemic sclerosis (scleroderma) is characterized by immunologic abnormalities, injury of endothelial cells, and tissue fibrosis. Abnormal oxidative stress has been documented in scleroderma and linked to fibroblast activation. Since platelet-derived growth factor (PDGF) stimulates the production of reactive oxygen species (ROS) and since IgG from patients with scleroderma reacts with human fibroblasts, we tested the hypothesis that patients with scleroderma have serum autoantibodies that stimulate the PDGF receptor (PDGFR), activating collagen-gene expression.

Methods We analyzed serum from 46 patients with scleroderma and 75 controls, including patients with other autoimmune diseases, for stimulatory autoantibodies to PDGFR by measuring the production of ROS produced by the incubation of purified IgG with mouse-embryo fibroblasts carrying inactive copies of PDGFR or chains or the same cells expressing PDGFR or . Generation of ROS was assayed with and without specific PDGFR inhibitors. Antibodies were characterized by immunoprecipitation, immunoblotting, and absorption experiments.

Results Stimulatory antibodies to the PDGFR were found in all the patients with scleroderma. The antibodies recognized native PDGFR, inducing tyrosine phosphorylation and ROS accumulation. Autoantibody activity was abolished by preincubation with cells expressing the PDGFR chain or with recombinant PDGFR or by PDGFR tyrosine kinase inhibitors. Stimulatory PDGFR antibodies selectively induced the Ha-Ras-ERK1/2 and ROS cascades and stimulated type I collagen–gene expression and myofibroblast phenotype conversion in normal human primary fibroblasts.

Conclusions Stimulatory autoantibodies against PDGFR appear to be a specific hallmark of scleroderma. Their biologic activity on fibroblasts strongly suggests that they have a causal role in the pathogenesis of the disease.

Source Information

From the Dipartimento di Scienze Mediche e Chirurgiche, Sezione di Clinica Medica, Università Politecnica delle Marche, Ancona (S.S.B., F.B., M.L., T.S., M.M., P.F., P.S., A.G.); the Sezione di Fisiologia (M.S.) and the Dipartimento di Biologia e Patologia Molecolare e Cellulare, Centro di Endocrinologia ed Oncologia Sperimentale del CNR (E.V.A.), Università Federico II, Naples; the Dipartimento di Genetica, Biologia e Biochimica and the Research Center for Experimental Medicine, Università di Torino, Turin (A.F.) — all in Italy; and Schepens Eye Research Institute, Harvard Medical School, Boston (A.K.).

Address reprint requests to Dr. Gabrielli at the Dipartimento di Scienze Mediche e Chirurgiche–Università Politecnica delle Marche, Polo Didattico, Via Tronto 10, 60020 Ancona, Italy, or at a.gabrielli{at}univpm.it, or to Dr. Avvedimento at the Dipartimento di Biologia e Patologia Molecolare e Cellulare, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Università Federico II, Via Pansini 5, 80131 Napoli, Italy, or at avvedim{at}unina.it.

Full Text of this Article

Related Letters:

Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma
Okamoto H., Lozano E., Segarra M., Cid M. C., Gabrielli A., Baroni S. S., Avvedimento E. V., Tan F. K.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:1278-1280, Sep 21, 2006. Correspondence

This article has been cited by other articles:

• Terrier, B, Tamby, M C, Camoin, L, Guilpain, P, Berezne, A, Tamas, N, Broussard, C, Hotellier, F, Humbert, M, Simonneau, G, Guillevin, L, Mouthon, L (2010). Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 69: 428-433 [Abstract] [Full Text]  
• Daoussis, D., Liossis, S.-N. C., Tsamandas, A. C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Karampetsou, M., Yiannopoulos, G., Andonopoulos, A. P. (2010). Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49: 271-280 [Abstract] [Full Text]  
• Simms, R. W., Lafyatis, R. (2010). Rituximab: a potential therapeutic advance in scleroderma: What is the evidence?. Rheumatology (Oxford) 49: 201-202 [Full Text]  
• Hunzelmann, N, Brinckmann, J (2010). What are the new milestones in the pathogenesis of systemic sclerosis?. Ann Rheum Dis 69: i52-i56 [Abstract] [Full Text]  
• Garcia-Gonzalez, E., Selvi, E., Balistreri, E., Lorenzini, S., Maggio, R., Natale, M.-R., Capecchi, P.-L., Lazzerini, P.-E., Bardelli, M., Laghi-Pasini, F., Galeazzi, M. (2009). Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford) 48: 1050-1056 [Abstract] [Full Text]  
• Demoulin, J.-B., Kampe, O., Rorsman, F., Kapoor, R., Kapoor, J. R., Gabrielli, A., Avvedimento, E. V., Krieg, T. (2009). Scleroderma. NEJM 361: 826-827 [Full Text]  
• Overbeek, M. J., Vonk, M. C., Boonstra, A., Voskuyl, A. E., Vonk-Noordegraaf, A., Smit, E. F., Dijkmans, B. A. C., Postmus, P. E., Mooi, W. J., Heijdra, Y., Grunberg, K. (2009). Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 34: 371-379 [Abstract] [Full Text]  
• Espinoza, J. L., Takamatsu, H., Lu, X., Qi, Z., Nakao, S. (2009). Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-{alpha} through an ERK1/2-dependent pathway. Int Immunol 21: 913-923 [Abstract] [Full Text]  
• Olivieri, A., Locatelli, F., Zecca, M., Sanna, A., Cimminiello, M., Raimondi, R., Gini, G., Mordini, N., Balduzzi, A., Leoni, P., Gabrielli, A., Bacigalupo, A. (2009). Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 114: 709-718 [Abstract] [Full Text]  
• Lei, H., Velez, G., Hovland, P., Hirose, T., Gilbertson, D., Kazlauskas, A. (2009). Growth Factors Outside the PDGF Family Drive Experimental PVR. IOVS 50: 3394-3403 [Abstract] [Full Text]  
• Zemskov, E. A., Loukinova, E., Mikhailenko, I., Coleman, R. A., Strickland, D. K., Belkin, A. M. (2009). Regulation of Platelet-derived Growth Factor Receptor Function by Integrin-associated Cell Surface Transglutaminase. J. Biol. Chem. 284: 16693-16703 [Abstract] [Full Text]  
• NAGASAKI, Y., MIYAMOTO, T., HENZAN, H., NAGAFUJI, K., HARADA, M., AKASHI, K. (2009). Longstanding Remission of Adult Onset Still's Disease Under Imatinib Therapy in a Patient with Chronic Myelogenous Leukemia. The Journal of Rheumatology 36: 1349-1350 [Full Text]  
• Abraham, D. J., Krieg, T., Distler, J., Distler, O. (2009). Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48: iii3-iii7 [Abstract] [Full Text]  
• Tyndall, A., Matucci-Cerinic, M., Muller-Ladner, U. (2009). Future targets in the management of systemic sclerosis. Rheumatology (Oxford) 48: iii49-iii53 [Abstract] [Full Text]  
• Gabrielli, A., Avvedimento, E. V., Krieg, T. (2009). Scleroderma. NEJM 360: 1989-2003 [Full Text]  
• Servettaz, A., Goulvestre, C., Kavian, N., Nicco, C., Guilpain, P., Chereau, C., Vuiblet, V., Guillevin, L., Mouthon, L., Weill, B., Batteux, F. (2009). Selective Oxidation of DNA Topoisomerase 1 Induces Systemic Sclerosis in the Mouse. J. Immunol. 182: 5855-5864 [Abstract] [Full Text]  
• Matucci-Cerinic, M., Czirjak, L. (2009). Immune-endothelial-nerve interaction: an explanation for the failure of the gastrointestinal system in systemic sclerosis?. Ann Rheum Dis 68: 609-610 [Full Text]  
• Lei, H., Kazlauskas, A. (2009). Growth Factors Outside of the Platelet-derived Growth Factor (PDGF) Family Employ Reactive Oxygen Species/Src Family Kinases to Activate PDGF Receptor {alpha} and Thereby Promote Proliferation and Survival of Cells. J. Biol. Chem. 284: 6329-6336 [Abstract] [Full Text]  
• Takamatsu, H., Espinoza, J. L., Lu, X., Qi, Z., Okawa, K., Nakao, S. (2009). Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia Stimulate Peripheral Blood Mononuclear Cells to Secrete TNF-{alpha} and IFN-{gamma}. J. Immunol. 182: 703-710 [Abstract] [Full Text]  
• Sabnani, I., Zucker, M. J., Rosenstein, E. D., Baran, D. A., Arroyo, L. H., Tsang, P., Zubair, M., Rivera, V. (2009). A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 48: 49-52 [Abstract] [Full Text]  
• Aden, N., Shiwen, X., Aden, D., Black, C., Nuttall, A., Denton, C. P., Leask, A., Abraham, D., Stratton, R. (2008). Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 47: 1754-1760 [Abstract] [Full Text]  
• Kapur, R., Ebeling, S., Hagenbeek, A. (2008). B-cell involvement in chronic graft-versus-host disease. haematol 93: 1702-1711 [Abstract] [Full Text]  
• Lozano, E, Segarra, M, Garcia-Martinez, A, Hernandez-Rodriguez, J, Cid, M C (2008). Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 67: 1581-1588 [Abstract] [Full Text]  
• Trojanowska, M. (2008). Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47: v2-v4 [Abstract] [Full Text]  
• Khanna, D. (2008). A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index. Rheumatology (Oxford) 47: v31-v32 [Abstract] [Full Text]  
• Moreno-Romero, J. A., Fernandez-Aviles, F., Carreras, E., Rovira, M., Martinez, C., Mascaro, J. M. Jr (2008). Imatinib as a Potential Treatment for Sclerodermatous Chronic Graft-vs-Host Disease. Arch Dermatol 144: 1106-1109 [Full Text]  
• Balada, E, Simeon-Aznar, C P, Ordi-Ros, J, Rosa-Leyva, M, Selva-O'Callaghan, A, Pardos-Gea, J, Fonollosa-Pla, V, Vilardell-Tarres, M (2008). Anti-PDGFR-{alpha} antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 67: 1027-1029 [Abstract] [Full Text]  
• Behr, J., Ryu, J. H. (2008). Pulmonary hypertension in interstitial lung disease. Eur Respir J 31: 1357-1367 [Abstract] [Full Text]  
• Andrae, J., Gallini, R., Betsholtz, C. (2008). Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22: 1276-1312 [Abstract] [Full Text]  
• Terrier, B., Tamby, M. C., Camoin, L., Guilpain, P., Broussard, C., Bussone, G., Yaici, A., Hotellier, F., Simonneau, G., Guillevin, L., Humbert, M., Mouthon, L. (2008). Identification of Target Antigens of Antifibroblast Antibodies in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 177: 1128-1134 [Abstract] [Full Text]  
• Sfikakis, P. P., Gorgoulis, V. G., Katsiari, C. G., Evangelou, K., Kostopoulos, C., Black, C. M. (2008). Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47: 735-737 [Full Text]  
• Fineschi, S., Cozzi, F., Burger, D., Dayer, J.-M., Meroni, P. L., Chizzolini, C. (2007). Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. Rheumatology (Oxford) 46: 1779-1785 [Abstract] [Full Text]  
• Roman, M. J., Salmon, J. E. (2007). Cardiovascular Manifestations of Rheumatologic Diseases. Circulation 116: 2346-2355 [Full Text]  
• Fonseca, C., Lindahl, G. E., Ponticos, M., Sestini, P., Renzoni, E. A., Holmes, A. M., Spagnolo, P., Pantelidis, P., Leoni, P., McHugh, N., Stock, C. J., Shi-Wen, X., Denton, C. P., Black, C. M., Welsh, K. I., du Bois, R. M., Abraham, D. J. (2007). A Polymorphism in the CTGF Promoter Region Associated with Systemic Sclerosis. NEJM 357: 1210-1220 [Abstract] [Full Text]  
• Servettaz, A, Guilpain, P, Goulvestre, C, Chereau, C, Hercend, C, Nicco, C, Guillevin, L, Weill, B, Mouthon, L, Batteux, F (2007). Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 66: 1202-1209 [Abstract] [Full Text]  
• Mapara, M. Y. (2007). Stimulating results with stimulatory antibodies. Blood 110: 6-7 [Full Text]  
• Svegliati, S., Olivieri, A., Campelli, N., Luchetti, M., Poloni, A., Trappolini, S., Moroncini, G., Bacigalupo, A., Leoni, P., Avvedimento, E. V., Gabrielli, A. (2007). Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110: 237-241 [Abstract] [Full Text]  
• Okamoto, H., Lozano, E., Segarra, M., Cid, M. C., Gabrielli, A., Baroni, S. S., Avvedimento, E. V., Tan, F. K. (2006). Stimulatory autoantibodies to the PDGF receptor in scleroderma.. NEJM 355: 1278-1278 [Full Text]  
• Tan, F. K. (2006). Autoantibodies against PDGF receptor in scleroderma.. NEJM 354: 2709-2711 [Full Text]